Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) is a commercial-stage company creating a portfolio of targeted therapies to treat immune-mediated dermatological diseases and conditions. Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) Market Cap: $2.47B; Current Share Price: 20.57 USD Data by YCharts ZORYVE® - Time to Have Skin in This Game! The Company has...
Charlotte’s Web Holdings (OTCQX: CWBHF), a pioneer in hemp-derived CBD products, announced the completion of an audit of its 2019 hemp harvest, which is the primary source of its full spectrum extracts. The Company grows 100 percent of its Hemp in its American facilities located...
Neurotrope Inc, (NASDAQ: NTRP) announced a setback, with Bryostatin, its lead candidate for the treatment of Alzheimer’s, failing to meet its clinical endpoints of its mid-stage study. The Topline results from the confirmatory Phase 2 study of Bryostatin-1, in moderate to severe Alzheimer’s, failed to achieve...
A rare genetic disorder caused by the accumulation of glucocerebroside in cells of the macrophage-monocyte system, owing to the lack of the glucocerebrosidase enzyme, Gaucher primarily affects the liver and the spleen. The disease manifests as Type 1, the most common form, also known as...
BioXcel Therapeutics (NASDAQ: BTAI) is buoyed by the positive results from a Phase 1b clinical trial, to test the efficacy of BXCL501, its lead drug candidate for the treatment of agitation in patients suffering from Schizophrenia. The drug candidate was granted a fast track designation...
Ovid Therapeutics (NASDAQ: OVID), a biopharmaceutical company developing novel therapeutics for rare neurological disorders, announced the launch of a crucial phase 3 clinical trial in Angelman Syndrome named NEPTUNE. OV101, its lead candidate for the treatment of syndrome and Fragile X Syndrome is a delta-selective...
Obalon Therapeutics (NASDAQ: OBLN), the manufacturer of the first and only FDA-approved swallowable, gas-filled intragastric balloon system to combat obesity, has announced the grant of U.S patent no. 10,264,995 entitled “SYSTEMS AND METHODS FOR LOCATING AND/OR CHARACTERIZING INTRAGASTRIC DEVICES. This will help expand the company’s...
PhaseBio’s (NASDAQ: PHAS), PB2452 is the new drug on the block, which has received a breakthrough therapy status from the FDA in April 2019. The company’s stock rose by almost 32%, on the day it announced the news. It acts as a reversal agent for...
TG Therapeutics (NASDAQ: TGTX), a clinical stage company that is leading the innovation bandwagon in the field of novel therapies for B-cell malignancies and autoimmune diseases has had a great run at the stock market so far this year. Its stocks have almost doubled in 2019 owing...
Gonorrhoea, caused by a bacterial pathogen N. gonorrhoea, is the second most commonly reported sexually transmitted disease in the U.S alone. The data made available by Centres for Disease Control and Prevention (CDC) shows that in 2017, a total of 555,608 cases of gonorrhoea were reported...
